Loading...
XLON
CNSL
Market cap5mUSD
Oct 13, Last price  
1.75GBP
Name

Omega Diagnostics Group PLC

Chart & Performance

D1W1MN
XLON:CNSL chart
P/E
P/S
0.55
EPS
Div Yield, %
Shrs. gr., 5y
13.27%
Rev. gr., 5y
-11.05%
Revenues
8m
-11.63%
0003,492,0005,438,0006,199,0007,902,00011,124,00011,262,89811,593,87012,105,31912,743,89614,246,93013,552,7268,756,7569,818,6628,734,8638,539,0007,546,000
Net income
-4m
L+173.95%
-73,000-85,0000238,000221,000187,00031,000527,000582,266692,851739,046571,912713,261-7,269,597974,253-6,828,312-2,104,310-1,409,000-3,860,000
CFO
-3m
L-2.38%
-63,000-78,000311,000600,000170,000322,000673,0001,014,9531,669,1071,247,8931,453,6762,011,324-828,497368,819547,607-2,419,589-3,229,000-3,152,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Omega Diagnostics Group PLC is a company dedicated to the development, manufacturing, and global supply of medical diagnostic products. Its extensive market reach includes the United Kingdom, mainland Europe, North and South America, India, various East Asian nations, Africa, and the Middle East, with distribution to approximately 75 countries worldwide. The business is structured into two main operating divisions: Health and Nutrition, and Global Health and Other. The Health and Nutrition segment is responsible for the research, creation, and production of diagnostic kits, such as those under the Foodprint brand, which are designed to detect immune responses to different foods. This division also offers clinical analysis services to the general public, medical clinics, and healthcare practitioners, in addition to supplying the Food Detective, a consumer-grade food sensitivity test. The Global Health and Other segment focuses on the research, development, production, and commercialization of diagnostic tools for infectious diseases. Key offerings from this segment include VISITECT CD4, an advanced rapid diagnostic test for managing HIV patients, the AbC-19 kit for COVID-19 antibody detection, and other COVID-19 antigen and antibody testing solutions. Omega Diagnostics' diverse range of products is provided to hospitals, medical clinics, laboratories, and other healthcare professionals. The company was established in 1987 and is headquartered in Alva, United Kingdom.
IPO date
Mar 18, 2004
Employees
91
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT